A 69-Year Old Man With Metastatic BRAF V600E-Mutated Metastatic NSCLC
Case: A 69-Year Old Man With MetastaticBRAFV600EMutated Metastatic NSCLC
Initial presentation
Clinical workup
Treatment and Follow-Up
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More